Journal of Drugs in Dermatology

View more issues:

Articles in Nov-Dec, 2004 issue of Journal of Drugs in Dermatology

• Treatment of glossodynia with olanzapine
• NDA filed for Cellegesic ointment for the treatment of chronic anal fissures
• Survival of Apligraf® in acute human wounds
• A novel non-thermal non-ablative full panel LED photomodulation device for reversal of photoaging: digital microscopic and clinical results in various skin types
  by Robert A. Weiss
• Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine
  by Edward L. Lain
• Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements
• Cancer risk in carriers of the gene for xeroderma pigmentosum
• Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type A
  by Dee Anna Glaser
• Allergic contact dermatitis to propolis
  by Patricia T. Ting
• Blood test for the detections of antibodies to HSV-1 and HSV-2
• Serum protein patterns in participants with mycosis fungoides/cutaneous T-cell lymphoma, psoriasis, or normal skin
• 5-Aminolevulinic Acid Photodynamic Therapy: a therapeutic platform in dermatology
  by Perry Robins
• Hypothesis: patients with dermatitis herpetiformis may be predisposed to depression and aggression
  by M.R. Namazi
• Treatment of nevus comedonicus with topical tazarotene and calcipotriene
  by Steven B. Deliduka
• To study the use of humanized CD25 in preventing the relapse of psoriasis vulgaris
• Eradication of basal cell cancer in an HIV positive patient with topical imiquimod
  by Don R. Scott
• A case of livedoid vasculopathy in a 22-year-old man
  by Aimee Leonard
• Lichenoid drug eruption probably associated with rofecoxib
• Celecoxib in preventing skin cancer in patients with actinic keratoses
• To study the effects of CD25 and low dose Cyclosporin in the treatment of active psoriasis vulgaris
• Fluorouracil topical cream contraindicated in DPD enzyme deficiency
• Phase III randomized study of oral acyclovir in infants with herpes simplex virus infection involving the central nervous system
• Myositis in children
• Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis
  by Alice B. Gottlieb
• Lichen nitidus treated with topical tacrolimus
  by Clifton R. Dobbs
• Infliximab associated with risk of hematologic, neurologic adverse events
• Photo protection by thalidomide in patients with chronic cutaneous and systemic lupus erythematous: discordant effects on minimal erythema dose and sunburn cell formation
• Study of skin tumors in tuberous sclerosis
• Clinical, laboratory, and epidemiologic characterization of individuals and families at high risk of melanoma
• Etanercept and warts
  by David R. Adams
• Hyperpigmentation: a review of common treatment options
  by Kimberly A. Cayce
• Tazoral rejected by FDA panel for psoriasis
• Study of mast cell precursors
• Laser-mediated photodynamic therapy of lichen sclerosus
  by Macrene Alexiades-Armenakas
• Col-101 enters Phase III clinical trials for rosacea
• FDA approves Botox for hyperhidrosis
• Immunetics, Inc., announces approval of anthrax quick ELISA test
• Response of ulcerated perineal hemangiomas of infancy to becaplermin gel, a recombinant human platelet-derived growth factor
• T4N5 liposomal lotion in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant
• Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine
  by A. Kapp
• Acrokeratosis Verruciformis of Hopf: a localized variant
  by Iqbal Bukhari
• FDA approves MAL-PDT for actinic keratoses
• Tinea capitis in a dermatology center in the city of Fortaleza, brazil: the role of Trichophyton tonsurans
• Tigecycline in the treatment of selected serious infections caused by vancomycin-resistant enterococcus or methicillin-resistant staphylococcus aureus
• Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source
  by Michael H. Gold
• A letter from the Editor-in-Chief
  by Perry Robins
• Medication and health care service utilization related to depressive symptoms in older adults with psoriasis
  by Amit S. Kulkarni
• Thermage announces approval of new indication
• Atrix and Fujisawa submit NDA for topical dapsone gel in the treatment of acne vulgaris
• Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis
• Red light laser photodynamic therapy of Bowen's disease
  by Eric C. Parlette
• Facial tolerability of topical retinoid therapy
  by James Leyden
• Oops! Kids don't get more sun than anyone else
• Treatment of acne vulgaris with a pulsed dye laser. A randomized controlled trial
• Study of talabostat and cisplatin in advanced melanoma
• Photodynamic therapy for the treatment of acne: a pilot study
  by Amy Forman Taub
• Clarinex syrup approved for children
• The medical uses and side effects of etanercept with a focus on cutaneous disease
  by Noah Scheinfeld
• Genzyme completes phase IV study of Fabrazyme for Fabry's disease
• Effect of tissue ultrafiltration on skin flap survival
• Peripheral stem cell transplantation plus monoclonal antibody therapy in treating patients with high-risk hematologic cancer, refractory breast or kidney cancer, or melanoma
• The Use of a novel intense pulsed light and heat source and ALA-PDT in the treatment of moderate to severe inflammatory acne vulgaris
  by Michael H. Gold